|
Thursday 25th February 2021 |
Text too small? |
In November 2020 Gentrack Group Limited (NZX/ASX: GTK) (“Gentrack”) advised that it expected that the full year EBITDA run rate for FY21 would be well below that of the H2 FY20 run rate and that FY21 profitability may be reduced closer to break-even depending on the levels of future product investment and other factors.
Gentrack now provides the following outlook update:
•FY21 revenues are expected to be close to or slightly ahead of FY20 revenues of $100.5m
•FY21 EBITDA is expected to be around $5m on the basis that research and development (R&D) costs are expensed
•Incremental R&D costs are expected to be ~$3m/quarter from Q3 FY21
•The company expects to be net cashflow positive in FY21, building on the $16.8m of net cash reported at 30th September 2020.
Profit and cashflow are expected to be weighted to H1 FY21 given the incremental R&D spend forecast for H2.
Please see the link below for details:
Source: Gentrack Group Limited
No comments yet
Devon Funds Morning Note - 29 September 2026
HGH publishes Annual Report, Climate Statement, AGM date
HLG Full Year Results for the period ending 1 August 2026
SKC - Issue of LTI Restricted Share Rights
NZX - BNP Paribas accredited as NZX Participant
September 29th Morning Report
GEN - GENERAL CAPITAL (NZX: GEN)
AFT - Maxigesic IV Licensed for Japan
BIT - Net Asset Values as at 24 September 2026
TEM - Transaction in Own Shares